Podcast: Using Antibodies to Treat Alzheimer’s a No-Brainer

By Marc Dresner, Senior Editor, IBC Life Sciences

While antibody therapies today are most commonly associated with oncology and inflammatory diseases, the next big breakthroughs may be on the neurology front.

Dr. Trudi Veldman, Senior Director of Biologics Generation at AbbVie Bioresearch Center, says deploying bispecifics as a “Trojan Horse” to enhance transport across the blood brain barrier could finally satisfy some extreme unmet needs.

“I see a lot of opportunities around Alzheimer’s, Multiple Sclerosis and Parkinson’s disease.”

“I see a lot of opportunities around neurological diseases, such as Alzheimer’s, Multiple Sclerosis and Parkinson’s disease,” said Veldman.

In this podcast interview for Inside Antibody Engineering, Dr. Veldman explains:

• Why she thinks antibody applications in neurology look so promising

• Where she sees impressive progress elsewhere in the field

• Why Fc receptor biology needs more attention and more!

Listen to the podcast or download a transcript here!

Editor’s note: Dr. Trudi Veldman will be chairing the Antibody Therapeutics for Non-Cancer Indications track at the Antibody Engineering and Therapeutics Conference taking place December 7-10 in San Diego.

Click here for an agenda. 

Or for more information visit: www.ibclifesciences.com/antibodyeng

(Ps. SAVE $100 when you register with code D15172BLOG!)

ABOUT THE AUTHOR/INTERVIEWER
Marc Dresner is sr. editor and special communication project lead with IBC Life Sciences. He is the former executive editor of Pharma Market Research Report, a publication for market research professionals specializing in pharmaceuticals and life sciences. He may be reached at mdresner@iirusa.com. Follow him @mdrezz.

Share this article with your social network, just click below to share now!

Share |

Who will be able to enter the biosimilars market?

A recent article at Reuters looks at the difficulty many could face entering the biosimilars market. Ludwig Burger states that he believes due to the difficulties of entering the market, it will be limited to a small circle of specialist companies. Currently, the only successful biosimiars manufactured are human growth hormones, but the next step will probably look towards therapeutic antibodies. Biosimilars, although generic versions of biologics, will only present the market with 20-30% discounts, but will see sales growth in terms of 2-3 times faster than the other generics on the market. Read the full article here.

So, now we want to hear from you. What do you think about the battle over biosimilars?

IIR’s 2nd Annual Business of Biosimilars conference delivers effective strategies to navigate scientific, regulatory, economic, and legal challenges you face to remain competitive in commercializing your biosimilar portfolio in the United States and abroad.

Share this article with your social network, just click below to share now!

Share |